BMS and 2seventy bio Announce Topline Results from KarMMa-3 Trial: Abecma Significantly Improves Progression-Free Survival vs Standard Regimens in RRMM 


Source URL: https://www.myeloma.org/news-events/multiple-myeloma-news/bms-2seventybio-topline-results-karmma-3-trial